Shillong Herald

Profacgen Established PROTAC Technology Platform for Research Use

 Breaking News
  • No posts were found

Profacgen Established PROTAC Technology Platform for Research Use

September 01
10:35 2021
Profacgen recently established a PROTAC technology platform to assist scientists with their research.

New York, USA – August 31, 2021 – Profacgen, a state-of-the-art protein service provider located in USA that provides custom protein services in the biological sciences, recently established a PROTAC technology platform to assist scientists with their research.

The proteolytic targeting chimera (PROTAC) is a small, miscellaneous molecule consisting of two active domains and a linker that can remove specific unwanted proteins. PROTAC does not act as a conventional enzyme inhibitor, but acts by inducing selective intracellular proteolysis. PROTAC consists of two covalently linked protein binding molecules: one can bind to E3 ubiquitin ligase, and the other can bind to the target protein to be degraded. Recruitment of E3 ligase to the target protein can lead to proteasome ubiquitination and subsequent degradation of the target protein. Because PROTAC only needs to bind to its target with high selectivity (instead of inhibiting the enzymatic activity of the target protein), there are many efforts to transform previously ineffective inhibitor molecules into PROTAC for next-generation drugs.

According to the great advantages of PROTAC in drug research and development, the PROTAC technology platform was established by the Profacgen Protein Chemistry Department, a high-affinity small molecule compound library and small molecule fragments of popular target proteins were established, a wide range of high-affinity small molecule molecules and small molecule fragments of E3 ligases were analyzed, and PROTAC models of adaptor and non-adaptor systems were designed. These accumulated compound libraries can be used for rapid and efficient ligand and targeted protein design, greatly improving the drug development process of PROTAC.

At present, a variety of PROTAC services are available at Profacgen, including:

• E3 ligase and target proteins development services
Ligand Discovery and Design Service
• PROTAC in vitro evaluation
PROTAC in vivo evaluation
• Targeted Protein Degradation

“Our experienced team supported by cutting-edge facilities enable us to be your trusted partner.” Commented Crystal, the chief marketing staff at Profacgen.

Detailed information about the list of PROTAC services offered by Profacgen can be viewed here: https://www.profacgen.com/protac.htm.

Media Contact
Company Name: Profacgen
Contact Person: Ellen
Email: Send Email
Phone: 1-516-855-7709
Country: United States
Website: https://www.profacgen.com

Related Articles